CEO: Benjamin Freedman, PhD

Visit Website

Limax Biosciences, a spinout from Harvard and MIT, is building the next generation of bioinspired surgical adhesives and hemostats. At the core of their platform is Hemomax, a biodegradable hydrogel that mimics the sticky, resilient slime of slugs—engineered to adhere strongly to wet, bleeding, and moving tissue surfaces. The company's innovation is designed to address critical unmet needs in surgery, trauma, and maternal health.

While the company’s initial clinical focus is on postpartum hemorrhage (PPH)—a leading cause of maternal death worldwide—the platform has broad applicability across surgery, trauma care, and drug delivery. Hemomax’s novel properties are attracting significant clinical interest as a potential game-changer in surgical care.